StockData
LB Pharmaceuticals Inc logo

LB Pharmaceuticals Inc (LBRX) stock

LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$40.06−0.24 (-0.60%)

Close on Nov 18, 2026Market cap $1.29BP/E –Yield –

Earnings

LB Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 25, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$1.79
-$0.61 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of LB Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close––-$1.79Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open––-$1.71Release
Q1 FY2026ended Mar 31, 2026May 12, 2026after the close––-$0.67Release
Q4 FY2025ended Dec 31, 2025Mar 26, 2026after the close––-$0.45Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open––-$0.61Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

LB Pharmaceuticals has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When LB Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases LB Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?